Serum Nerve Growth Factor as a Biomarker for Chemotherapy-Induced Peripheral Neuropathy: A Cross-Sectional Study
DOI:
https://doi.org/10.37275/bsm.v9i6.1292Keywords:
Biomarker, Cancer, Chemotherapy-induced peripheral neuropathy, Nerve growth factor, Toronto clinical scoring systemAbstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment. Nerve growth factor (NGF) plays a crucial role in neuronal health and has been implicated in CIPN development. This study investigated the relationship between serum NGF levels and CIPN in cancer patients undergoing chemotherapy.
Methods: A cross-sectional study was conducted on 60 cancer patients receiving chemotherapy at Dr. M. Djamil General Hospital Padang, Indonesia, from June to October 2024. Serum NGF levels were measured, and CIPN was assessed using the Toronto Clinical Scoring System (TCSS). The relationship between NGF and CIPN was analyzed using the Mann-Whitney test.
Results: The median serum NGF level was significantly lower in patients with CIPN (n=43) compared to those without CIPN (n=17) (103.26 pg/ml vs. 148.91 pg/ml, p=0.029). No significant association was found between chemotherapy regimens and CIPN or NGF levels.
Conclusion: Lower serum NGF levels are associated with CIPN in cancer patients undergoing chemotherapy. NGF may serve as a potential biomarker for CIPN, aiding in early detection and management. Further research is needed to explore the clinical utility of NGF as a predictive and monitoring tool for CIPN.
Authors
- Rifki Irsyad1
- Restu Susanti2*
- Fanny Adhy Putri2
- Yuliarni Syafrita2
- Syarif Indra2
- Reno Bestari2
- 1Residency in Department of Neurology, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 2Staff, Department of Neurology, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia Indonesia
Corresponding author Restu Susanti — restususanti@yahoo.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
